Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Hepatology. 2016 Mar 22;63(6):1796–1808. doi: 10.1002/hep.28497

Figure 1. Cost-effectiveness acceptability curves for doubled HCV case-finding in prison combined with (A) status quo treatments (B) 8–12 week IFN-free DAAs in prison.

Figure 1

Incremental comparisons shown are: (A) Doubled HCV case-finding in prison combined with status quo treatments compared to status quo testing/treatment; (B) Doubled HCV case-finding combined with 8–12 week IFN-free DAAs in prison compared to doubled case-finding with status quo treatments.